Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis

Gregory P. Kaufman, Angela Dispenzieri, Morie Gertz, Martha Lacy, Francis K. Buadi, Suzanne R. Hayman, Nelson Leung, David M Dingli, John A. Lust, Yi Lin, Prashant Kapoor, Ronald S. Go, Steven R. Zeldenrust, Robert A. Kyle, S Vincent Rajkumar, Shaji K Kumar

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Despite successful treatment of the clonal plasma cell implicated in its pathogenesis, patients with AL amyloidosis (AL) experience significant morbidity related to underlying amyloid mediated organ dysfunction. While normalization of the serum free light chain measurements [normal ratio of involved and uninvolved free light chains (nFLCr)] is the goal of therapy and centerpiece of hematologic response criteria, achieving (or not achieving) meaningful organ response (OR) is clinically significant for its implications on long-term symptomatology as well as overall survival (OS), and remains the ultimate goal of treatment. Expectations for organ recovery following successful therapy leading to nFLCr in AL remain poorly described. We evaluated the timeframe and predictive factors for OR, and long-term outcome, in 313 AL patients who achieved nFLCr following therapy initiation. OR was seen in 80% of surviving AL patients within 1-year of nFLCr. Patients achieving early OR within 1 year of nFLCr had superior OS compared with those who despite obtaining nFLCr did not achieve early OR. We further evaluated factors predicting OR and OS among patients achieving nFLCr. Higher values of dFLC (involved-uninvolved) at diagnosis predict OR, and early OR predicts improved OS following successful hematologic therapy in AL.

Original languageEnglish (US)
Pages (from-to)181-186
Number of pages6
JournalAmerican Journal of Hematology
Volume90
Issue number3
DOIs
StatePublished - Mar 1 2015

Fingerprint

Tissue Survival
Amyloidosis
Light
Serum
Survival
Therapeutics
Plasma Cells
Amyloid
Morbidity

ASJC Scopus subject areas

  • Hematology

Cite this

Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. / Kaufman, Gregory P.; Dispenzieri, Angela; Gertz, Morie; Lacy, Martha; Buadi, Francis K.; Hayman, Suzanne R.; Leung, Nelson; Dingli, David M; Lust, John A.; Lin, Yi; Kapoor, Prashant; Go, Ronald S.; Zeldenrust, Steven R.; Kyle, Robert A.; Rajkumar, S Vincent; Kumar, Shaji K.

In: American Journal of Hematology, Vol. 90, No. 3, 01.03.2015, p. 181-186.

Research output: Contribution to journalArticle

Kaufman, Gregory P. ; Dispenzieri, Angela ; Gertz, Morie ; Lacy, Martha ; Buadi, Francis K. ; Hayman, Suzanne R. ; Leung, Nelson ; Dingli, David M ; Lust, John A. ; Lin, Yi ; Kapoor, Prashant ; Go, Ronald S. ; Zeldenrust, Steven R. ; Kyle, Robert A. ; Rajkumar, S Vincent ; Kumar, Shaji K. / Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. In: American Journal of Hematology. 2015 ; Vol. 90, No. 3. pp. 181-186.
@article{55d7b20ee6694343a34030c3e43c29ba,
title = "Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis",
abstract = "Despite successful treatment of the clonal plasma cell implicated in its pathogenesis, patients with AL amyloidosis (AL) experience significant morbidity related to underlying amyloid mediated organ dysfunction. While normalization of the serum free light chain measurements [normal ratio of involved and uninvolved free light chains (nFLCr)] is the goal of therapy and centerpiece of hematologic response criteria, achieving (or not achieving) meaningful organ response (OR) is clinically significant for its implications on long-term symptomatology as well as overall survival (OS), and remains the ultimate goal of treatment. Expectations for organ recovery following successful therapy leading to nFLCr in AL remain poorly described. We evaluated the timeframe and predictive factors for OR, and long-term outcome, in 313 AL patients who achieved nFLCr following therapy initiation. OR was seen in 80{\%} of surviving AL patients within 1-year of nFLCr. Patients achieving early OR within 1 year of nFLCr had superior OS compared with those who despite obtaining nFLCr did not achieve early OR. We further evaluated factors predicting OR and OS among patients achieving nFLCr. Higher values of dFLC (involved-uninvolved) at diagnosis predict OR, and early OR predicts improved OS following successful hematologic therapy in AL.",
author = "Kaufman, {Gregory P.} and Angela Dispenzieri and Morie Gertz and Martha Lacy and Buadi, {Francis K.} and Hayman, {Suzanne R.} and Nelson Leung and Dingli, {David M} and Lust, {John A.} and Yi Lin and Prashant Kapoor and Go, {Ronald S.} and Zeldenrust, {Steven R.} and Kyle, {Robert A.} and Rajkumar, {S Vincent} and Kumar, {Shaji K}",
year = "2015",
month = "3",
day = "1",
doi = "10.1002/ajh.23898",
language = "English (US)",
volume = "90",
pages = "181--186",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis

AU - Kaufman, Gregory P.

AU - Dispenzieri, Angela

AU - Gertz, Morie

AU - Lacy, Martha

AU - Buadi, Francis K.

AU - Hayman, Suzanne R.

AU - Leung, Nelson

AU - Dingli, David M

AU - Lust, John A.

AU - Lin, Yi

AU - Kapoor, Prashant

AU - Go, Ronald S.

AU - Zeldenrust, Steven R.

AU - Kyle, Robert A.

AU - Rajkumar, S Vincent

AU - Kumar, Shaji K

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Despite successful treatment of the clonal plasma cell implicated in its pathogenesis, patients with AL amyloidosis (AL) experience significant morbidity related to underlying amyloid mediated organ dysfunction. While normalization of the serum free light chain measurements [normal ratio of involved and uninvolved free light chains (nFLCr)] is the goal of therapy and centerpiece of hematologic response criteria, achieving (or not achieving) meaningful organ response (OR) is clinically significant for its implications on long-term symptomatology as well as overall survival (OS), and remains the ultimate goal of treatment. Expectations for organ recovery following successful therapy leading to nFLCr in AL remain poorly described. We evaluated the timeframe and predictive factors for OR, and long-term outcome, in 313 AL patients who achieved nFLCr following therapy initiation. OR was seen in 80% of surviving AL patients within 1-year of nFLCr. Patients achieving early OR within 1 year of nFLCr had superior OS compared with those who despite obtaining nFLCr did not achieve early OR. We further evaluated factors predicting OR and OS among patients achieving nFLCr. Higher values of dFLC (involved-uninvolved) at diagnosis predict OR, and early OR predicts improved OS following successful hematologic therapy in AL.

AB - Despite successful treatment of the clonal plasma cell implicated in its pathogenesis, patients with AL amyloidosis (AL) experience significant morbidity related to underlying amyloid mediated organ dysfunction. While normalization of the serum free light chain measurements [normal ratio of involved and uninvolved free light chains (nFLCr)] is the goal of therapy and centerpiece of hematologic response criteria, achieving (or not achieving) meaningful organ response (OR) is clinically significant for its implications on long-term symptomatology as well as overall survival (OS), and remains the ultimate goal of treatment. Expectations for organ recovery following successful therapy leading to nFLCr in AL remain poorly described. We evaluated the timeframe and predictive factors for OR, and long-term outcome, in 313 AL patients who achieved nFLCr following therapy initiation. OR was seen in 80% of surviving AL patients within 1-year of nFLCr. Patients achieving early OR within 1 year of nFLCr had superior OS compared with those who despite obtaining nFLCr did not achieve early OR. We further evaluated factors predicting OR and OS among patients achieving nFLCr. Higher values of dFLC (involved-uninvolved) at diagnosis predict OR, and early OR predicts improved OS following successful hematologic therapy in AL.

UR - http://www.scopus.com/inward/record.url?scp=84923082032&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923082032&partnerID=8YFLogxK

U2 - 10.1002/ajh.23898

DO - 10.1002/ajh.23898

M3 - Article

C2 - 25388651

AN - SCOPUS:84923082032

VL - 90

SP - 181

EP - 186

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 3

ER -